Cargando…
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Targeting immune checkpoint pathways, such as programmed death ligand-1 (PD-L1, also known as CD274 or B7-H1) or its receptor programmed cell death-1 (PD-1) has shown improved survival for patients with numerous types of cancers, not limited to lung cancer, melanoma, renal cell carcinoma, and Hodgki...
Autores principales: | Mahoney, Kathleen M., Shukla, Sachet A., Patsoukis, Nikolaos, Chaudhri, Apoorvi, Browne, Edward P., Arazi, Arnon, Eisenhaure, Thomas M., Pendergraft, William F., Hua, Ping, Pham, Hung C., Bu, Xia, Zhu, Baogong, Hacohen, Nir, Fritsch, Edward F., Boussiotis, Vassiliki A., Wu, Catherine J., Freeman, Gordon J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6426808/ https://www.ncbi.nlm.nih.gov/pubmed/30564891 http://dx.doi.org/10.1007/s00262-018-2282-1 |
Ejemplares similares
-
Interaction of SHP-2 SH2 domains with PD-1 ITSM induces PD-1 dimerization and SHP-2 activation
por: Patsoukis, Nikolaos, et al.
Publicado: (2020) -
Effects of PD-1 Signaling on Immunometabolic Reprogramming
por: Boussiotis, Vassiliki A., et al.
Publicado: (2022) -
Runx1 and Runx3 Are Involved in the Generation and Function of Highly Suppressive IL-17-Producing T Regulatory Cells
por: Li, Lequn, et al.
Publicado: (2012) -
Revisiting the PD-1 pathway
por: Patsoukis, Nikolaos, et al.
Publicado: (2020) -
Personal neoantigen cancer vaccines: The momentum builds
por: Fritsch, Edward F, et al.
Publicado: (2014)